Olmesartan as an add-on to Amlodipine in Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Registration Number
- NCT00220233
- Lead Sponsor
- Sankyo Pharma Gmbh
- Brief Summary
This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 632
Inclusion Criteria
- Without antihypertensive pre-treatment mean seated BP greater than 160/100 mmHg
- Pre-treatment with amlodipine 5 or 10 mg: mean seated BP greater than or equal to 140/90 mmHg
Exclusion Criteria
- Secondary hypertension
- Any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mean change in trough seated diastolic blood pressure
- Secondary Outcome Measures
Name Time Method Percent of patients achieving target blood pressure goal Mean change in trough seated systolic BP Mean change in daytime, nighttime and 24 hour ambulatory blood pressure Safety and tolerability